- Home
- XYF vs BDTX Comparison
XYF vs BDTX Comparison
Compare XYF & BDTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | XYF | BDTX |
|---|---|---|
| Founded | 2014 | 2014 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 179.1M | 104.0M |
| IPO Year | 2018 | 2020 |
Fundamental Metrics
Financial Performance| Metric | XYF | BDTX |
|---|---|---|
| Price | $4.83 | $2.08 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | 47.9K | ★ 761.0K |
| Earning Date | 11-19-2026 | 11-05-2026 |
| Dividend Yield | ★ 11.53% | N/A |
| EPS Growth | N/A | ★ 130.71 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $0.90 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.30 | $1.60 |
| 52 Week High | $13.16 | $4.94 |
Technical Indicators
Market Signals| Indicator | XYF | BDTX |
|---|---|---|
| Relative Strength Index (RSI) | 43.34 | 63.38 |
| Support Level | $4.62 | $1.98 |
| Resistance Level | $5.15 | $2.28 |
| Average True Range (ATR) | 0.21 | 0.12 |
| MACD | -0.02 | 0.04 |
| Stochastic Oscillator | 21.25 | 89.81 |
Price Performance
Historical ComparisonAbout XYF X Financial each representing six
X Financial is a Cayman Islands-based technology-driven personal finance company. Along with its subsidiaries, the firm provides diversified investment opportunities to investors in China through its wealth management platform, Xiaoying Wealth Management. Loan products offered by the company include Xiaoying Card Loan, Xiaoying Preferred Loan, and Xiaoying Housing Loan. The company generates revenue from loan facilitation service, post-origination service, guarantee services provided and financing income.
About BDTX Black Diamond Therapeutics Inc.
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The foundation of companies has been built upon a deep understanding of cancer genetics, onco-protein structure and function, and medicinal chemistry. Its clinical-stage program, silevertinib (formerly BDTX-1535), a brain-penetrant, fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor, is currently being studied in a Phase 2 clinical trial in patients with epidermal growth factor receptor mutant (EGFRm) non-small cell lung cancer (NSCLC). The Company manages its operations as a single operating segment and single reportable segment.